Clinical Trials Logo

Vaccine Preventable Disease clinical trials

View clinical trials related to Vaccine Preventable Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04953130 Active, not recruiting - HPV Infection Clinical Trials

Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania

Add-Vacc
Start date: August 1, 2022
Phase: Phase 4
Study type: Interventional

Add-Vacc is an unblinded cluster-randomised trial (CRT) with two arms: (i) the national HPV vaccination programme (girls aged ~14 years, control arm) and (ii) the national programme plus single-dose male HPV vaccination given to a multi-year cohort of boys (intervention arm). The CRT will be conducted in 26 communities/clusters (13 per arm) in northern Tanzania. Boys aged 14 to 18 years in the intervention arm will receive one dose of the 4-valent HPV vaccine (Gardasil®) that protects against HPV 6, 11, 16, and 18. Population genital HPV prevalence in 18 to 21-year-olds will be compared between intervention clusters (female and male vaccination) and control clusters (female vaccination only) at 3 years after the intervention. Blood sampling for immune responses and adverse event data collection will be performed in a subset of 200 male subjects in selected intervention clusters.

NCT ID: NCT04817917 Active, not recruiting - Vaccine Reaction Clinical Trials

Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province

Start date: March 1, 2021
Phase: Phase 4
Study type: Interventional

This study is to evaluate the seroprevalence of neutralizing antibodies against Japanese encephalitis (JE) virus in children aged 6 years who were previously administered with 5 different immunization strategies by JE attenuated live vaccine (JEV-L) or/and inactivated vaccine (JEV-I). The secondary objective is to evaluate the immunogenicity of the booster dose of JEV-I at 6 years old for those previously immunized with 3 doses of JEV-I or those sequential administered with 1 dose of JEV-L and another dose of JEV-I.